Clonal expansion driven by leukemia-associated somatic mutations, such as DNMT3A, ASXL1, or TET2, are associated with an increased risk of blood cancers which is nearly tenfold compared to age-matched individuals who do not display detectable CHIP, with an absolute risk of progression is about 1% per year (Jaiswal et al., 2017). Here, STUB1 is linked to leukemia.